Healthcare Stocks: BioLineRx Jumps On Patents (BLRX, GNOM, ARRY, TSPT, AMLN)
BioLineRx Ltd (NASDAQ:BLRX) soared 3.88% to $2.41. United States Patent and Trademark Office has issued two Notices of Allowance for BL-1021. This is an orally available small molecule for treating neuropathic pain. The first has been issued for a patent application claiming BL-1021’s composition. The other Notice of Allowance is for a patent application claiming the use of BL-1021 for the treatment of pain.
Complete Genomics Inc (NASDAQ:GNOM) went up 7.35% to $2.19. The Company announced that it is taking steps to reduce cash consumption and has engaged Jefferies & Company to assist it in exploring strategic alternatives. The Company also plans to focus on development of clinical applications for its whole human genome sequencing service. Complete will maintain its current monthly capacity of approximately 1,000 genomes at 40x coverage or 500 genomes at 80x coverage.
Array Biopharma Inc (NASDAQ:ARRY) is down 0.44% to $3.37. The Company said that promising data on MEK162 in an ongoing Phase 2 trial of patients with BRAF and NRAS mutated advanced melanoma was presented at the American Society of Clinical Oncology Annual Meeting in Chicago.
Novacea Inc (NASDAQ:TSPT) moved down 1.50% to $6.55. The Company appointed John A. Kollins as Senior Vice President and Chief Business Officer, effective June 1, 2012.
The management of the Company is scheduled to present at the Jefferies 2012 Global Healthcare Conference in New York on June 7, 2012.
Amylin Pharmaceuticals Inc (NASDAQ:AMLN) soared 2.85% to $27.39 on a traded volume of 1.16 million shares. The Company drew four first-round bids valuing the company at $25 to $29 per share with Pfizer Inc. According to Bloomberg News, PFE dropping out of the process.
The Company will present data for BYDUREON™, BYETTA and SYMLIN injection at the 72nd Scientific Sessions of the American Diabetes Association from June 8-12, 2012, in Philadelphia.